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Abstract: The importance of in-
tratumour genetic and functional
heterogeneity is increasingly rec-
ognised as a driver of cancer
progression and survival outcome.
Understanding how tumour clonal
heterogeneity impacts upon thera-
peutic outcome, however, is still an
area of unmet clinical and scientific
need. TRACERx (TRAcking non-
small cell lung Cancer Evolution
through therapy [Rx]), a prospec-
tive study of patients with primary
non-small cell lung cancer (NSCLC),
aims to define the evolutionary
trajectories of lung cancer in both
space and time through multire-
gion and longitudinal tumour sam-
pling and genetic analysis. By
following cancers from diagnosis
to relapse, tracking the evolution-
ary trajectories of tumours in rela-
tion to therapeutic interventions,
and determining the impact of
clonal heterogeneity on clinical
outcomes, TRACERx may help to
identify novel therapeutic targets
for NSCLC and may also serve as a
model applicable to other cancer
types.
Introduction
Each patient’s cancer has a unique
genomic landscape, often comprised of
populations of genetically distinct, sepa-
rated subclones with the potential to
undergo dynamic evolutionary processes
throughout the disease course [1,2]. One
of the major challenges in achieving the
goal of precision medicine lies in obtaining
an accurate view of this genomic land-
scape, in order to choose the appropriate
therapeutic regimen [3]. Intratumour het-
erogeneity poses a challenge in that a
single tumour biopsy may not fully capture
the current or future tumour landscape
and merely represents a ‘‘snapshot’’ of the
disease in space and time. Several studies
have demonstrated branched evolution in
different tumour types, including breast
[4,5], pancreatic [6], kidney [7], colorectal
[8], and prostate [9] cancers, as well as
haematological malignancies such as
chronic lymphoblastic leukaemia [1] and
acute lymphoblastic leukaemia [10]. Un-
derstanding how tumour clonal heteroge-
neity impacts upon clinical outcome, and
how cancer subclones compete, adapt, and
evolve through the disease course in relation
to therapy, is an area of unmet clinical and
scientific need. Lung TRACERx (TRAcking
non-small cell lung Cancer Evolution
through therapy [Rx], ClinicalTrials.gov
number, NCT01888601), is a prospective
study in primary non-small cell lung cancer
(NSCLC), which through multiregion and
longitudinal tumour sampling and sequenc-
ing, aims to define the genomic landscape of
NSCLC and to understand the impact of
tumour clonal heterogeneity upon therapeu-
tic and survival outcome.
Overview of Lung TRACERx
Lung TRACERx incorporates longitu-
dinal sample collection from diagnosis to
relapse in order to investigate how each
cancer responds to treatment, the poten-
tial mutational processes and mechanisms
involved in drug resistance, and develop-
ment of metastatic disease. Although here
we discuss TRACERx in NSCLC, the
proposed longitudinal sample collection
and study template is also relevant to other
tumour types. TRACERx, conducted
across six sites in the United Kingdom
(London, Leicester, Manchester, Aber-
deen, Birmingham, and Cardiff), will enrol
842 patients with primary NSCLC stages
I-IIIA over an accrual period of four years
with a total five-year follow-up per patient.
Primary surgically resected NSCLC tu-
mours and associated lymph nodes, sur-
plus to diagnostic requirements, will be
subject to multiregion sampling and sub-
sequent whole-exome and/or whole-ge-
nome sequencing. In patients suffering
disease recurrence, consent will be ob-
tained for a further biopsy to assess how
the tumour clonal structure has changed
through therapy and disease progression.
The primary objectives of TRACERx are
to determine the relationship between
intratumour heterogeneity and clinical
outcome (disease-free survival [DFS] and
overall survival [OS]), and to establish the
impact of adjuvant platinum-containing
regimens on intratumour heterogeneity in
relapsed disease. The secondary objectives
include developing and validating an
intratumour heterogeneity index as a
prognostic or predictive biomarker and
identifying drivers of genomic instability,
metastatic progression, and drug resis-
tance by identifying and tracking the
dynamics of somatic mutational heteroge-
neity. TRACERx also aims to define
clonally dominant drivers of disease to
address the role of clonal driver domi-
nance in targeted therapeutic response,
and to guide lung cancer treatment
stratification. The sample collection per
patient and overall study schema are
summarised in Figure 1 and Figure 2,
respectively.
Spatial Heterogeneity and
Branched Evolution in NSCLC
Previous efforts to characterise the
cancer genome of NSCLC have involved
the analysis of copy number alterations
[11,12], targeted sequencing of candidate
cancer genes [13,14] and next-generation
sequencing of genomes and/or exomes
[15–18]. By interrogating the mutational
spectrum of tumours, these studies have
demonstrated its complex and heteroge-
neous genomic landscape from point
mutations to large structural variants,
and the high mutational burden of smok-
ing-related NSCLC. However, few studies
in NSCLC have investigated the clonal
and subclonal architecture of lung cancer
tumours and their evolution through
disease progression. The TRACERx con-
sortium has developed methods to analyse
the dynamics of genetic intratumour
heterogeneity within individual tumours
over time [7]. Distance-based phylogenetic
trees will be inferred from the variants,
insertions and deletions (INDELS), and
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structural variations observed in multi-
region exome sequence datasets from a
single tumour, allowing the discrimination
of conserved early genetic mutations
present at all sites of the primary tumour
from later somatic events present in parts
of the tumour and/or metastatic sites. This
estimated temporal ordering will give
insight into the potential relationships of
such changes with ploidy shifts, chromo-
somal instability, and mutational processes
that may change during the course of
tumour progression.
Histological Heterogeneity in
NSCLC
Lung cancer is a histologically highly
heterogeneous disease. Mixed lung tu-
mours containing more than one histolog-
ical type, such as adenosquamous tu-
mours, combined small-cell tumours
(small-cell combined with NSCLC), or
tumours with areas of histological dedif-
ferentiation are not uncommon. Within
adenocarcinomas, histological variety is
the rule, with most tumours showing a
mixture of patterns, the commonest being
lepidic/in situ, acinar, solid, papillary, and
micropapillary. Solid and micropapillary
patterns are associated with worse out-
come [19–21]. Some patterns show asso-
ciations with known driving mutations
[22,23], although these relationships are
incompletely described at present. Fur-
thermore, nuclear grade, which is not
currently routinely assessed, often shows
heterogeneity and is itself related to outcome
[24,25]. It is not known to what extent this
spatial histological heterogeneity reflects
genomic heterogeneity as opposed to epige-
netic or microenvironmental influences.
TRACERx aims to correlate histological
heterogeneity with genomic heterogeneity
and potentially improve the predictive
and prognostic value of histological
appearances in NSCLC.
Tumour Heterogeneity,
Outcome, and Impact of
Platinum Chemotherapy in
NSCLC
It is unclear why adjuvant chemother-
apy following surgery for primary NSCLC
is effective in some patients but not in
others. An increasing body of evidence
supports the association of patterns of
intratumour heterogeneity, in multivariate
analyses, with poor survival outcome in
NSCLC and other solid tumours [26].
Indeed, work from us and others has
shown that chromosomal instability, a
driver of intratumour heterogeneity, is
associated with cancer drug resistance,
and numerous studies have documented
the association of chromosomal instability
with poor outcome in NSCLC [26–31].
The impact of intratumour heterogeneity
on evolutionary fitness, together with the
documented relationship of heterogeneity
with drug resistance, supports the potential
predictive nature of this candidate bio-
marker. Cytotoxic therapies have also
been shown to influence the genomic
landscape of drug-resistant diseases
[32,33], which raises the concern that
increased genomic complexity in cytotoxic
refractory tumours may potentiate tumour
adaptation. However, studies to date are
based on the analysis of small retrospective
cohorts such that the true relationship
between intratumour heterogeneity and
clinical outcome, as well as the impact of
platinum-based chemotherapy on the tu-
mour genomic landscape, is currently
unknown. TRACERx will prospectively
assess whether an intratumour heteroge-
neity index can predict response to
adjuvant therapy, and attempt to validate
intratumour heterogeneity as an effective
prognostic and predictive biomarker inde-
pendent of known factors, such as tumour
stage.
Defining Drivers of Intratumour
Heterogeneity and Drug
Resistance
Deep sequencing analyses are revealing
vast clonal heterogeneity present in solid
tumours, including NSCLC, and the
spatial and temporal dynamics of cancer
subclones that emerge during the disease
course and following acquired drug resis-
tance [34,35]. We have shown that drivers
of intratumour heterogeneity can be
defined in vivo and that one mechanism
driving tumour heterogeneity in colo-
rectal cancer, DNA replication stress,
may be targetable [36]. Defining such
processes in longitudinal solid tumour
cohorts may have therapeutic relevance
in attempting to limit tumour heteroge-
neity, adaptation, and cancer evolution
[37]. TRACERx aims to develop an
improved understanding of the relation-
ship between phenotypic and genetic
intratumour heterogeneity with cancer
evolution, and identify further drivers of
genomic instability. Ultimately it is
hoped that this will support the devel-
opment of novel therapeutic approaches
to limit relapse and improve outcomes
in NSCLC.
Figure 1. Sample collection in TRACERx.
doi:10.1371/journal.pbio.1001906.g001
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Impact of Intratumour
Heterogeneity on Host
Immunity and Tumour Neo-
Antigenic Repertoire
Whilst evidence suggests that intratu-
mour heterogeneity may significantly limit
the antitumour activity of targeted thera-
peutics [38], its overall effect on the
anticancer immune response may be
beneficial, since high levels of intratu-
moural mutational diversity may generate
neo-antigens perceived by the immune
system as non-self, thus providing relevant
targets for immune-based therapies [38–
40]. TRACERx aims to provide a re-
source to define the impact of intratumour
heterogeneity on cancer immunity
throughout tumour evolution and therapy.
Through the integration of clinical and
tumour multiregion sequencing data with
immunological analysis, the consortium
will assess various aspects of tumour
immunobiology, including the overall
impact of distinct drivers of intratumour
heterogeneity on immune infiltration and
function, the proportion of tumour infil-
trating lymphocytes with the ability to
recognise neo-antigens, and whether novel
T cell receptors that recognise phospho-
peptides preferentially expressed by tu-
mour cells can be identified in patients,
with NSCLC serving as a platform for the
development of future immunotherapeutic
strategies.
Development of Minimally
Invasive Methods to Study
Tumour Evolution
Primary and metastatic tumours will be
genetically profiled to identify clonal and
subclonal driver mutations. However, our
analysis of the primary tumour is limited
to tissue surplus to diagnostic requirement,
albeit multiregional, and our analysis of
metastatic sites is likely to be restricted to
one location, emphasising the need to
develop less invasive approaches to follow
tumour evolution. Circulating biomarkers
have the potential to monitor minimal
residual disease, forecast early progression,
and document subclonal evolution
through therapy and acquired drug resis-
tance [41]. Here we propose to extend the
TRACERx consortium’s expertise in min-
imally invasive biomarker approaches to
monitor tumour subclonal evolution
through serial analysis of circulating-free
tumour DNA (cfDNA) and circulating
tumour cells (CTCs) before surgery and
throughout the disease course. We have
shown that cfDNA analysis is technically
Figure 2. Schematic of an integrated clinical approach to understanding the impact of intratumour heterogeneity upon disease
progression and clinical outcome. Abbreviations: cfDNA, circulating-free tumour DNA; CTCs, circulating tumour cells; FACS, fluorescence-
activated cell sorting; FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry. Lungs diagram adapted from ‘‘Lungs diagram simple’’ from
Patrick J. Lynch, Wikimedia Commons under CY-BY 2.5. Metastatic disease image from Haubner, et al. (2005) PLoS Med 2: e70. doi:10.1371/
journal.pmed.0020070. Images of FACS analysis, immunohistochemistry, and FISH obtained from the Swanton lab.
doi:10.1371/journal.pbio.1001906.g002
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straightforward with limited cost and has
demonstrable utility in disease monitoring
[35,42], and that CTC number in
NSCLC is an independent prognostic
biomarker [43]. TRACERx aims to ad-
dress how intratumour heterogeneity is
manifested in circulating biomarkers and
the extent to which the genetic landscape
of the primary and metastatic tumour is
reflected in CTCs and cfDNA. This
comparison will take into account the
limitations in tumour sampling and there-
fore the potential to identify genetic
aberrations in CTCs and cfDNA not
detected in the tumour tissue. By compar-
ing serial samples, TRACERx will deter-
mine whether cfDNA can detect residual
disease following surgery and predict
tumour recurrence, whether CTCs and
cfDNA in advanced metastatic disease can
represent further selection of subclones
over time, and whether CTCs and cfDNA
can provide insight into drug resistance
mechanisms.
Clonal Dominance and Clinical
Outcome
There is a pressing need to define early
driver events suitable for clinical drug trial
stratification and to assess prospectively
the role of drug target intratumour
heterogeneity in the early emergence of
resistance and poor DFS outcomes. Until
recently, the term ‘‘actionable mutation’’
was used to define the presence of a
somatic mutation or copy number event in
a single tumour biopsy that might suggest
a targeted therapeutic approach. Howev-
er, emerging evidence for intratumour
heterogeneity in breast cancer [44], renal
cell carcinoma [7], glioblastoma [45],
pancreatic cancer [6,46], and medullo-
blastoma [47] demands the consideration
of the role of clonal dominance when
defining actionable events. In patients with
an identified epidermal growth factor
receptor (EGFR)-activating mutation
treated with EGFR-targeted therapy, the
clonality of the mutation is generally
unknown, and yet it has been suggested
that subclonal EGFR somatic mutational
heterogeneity may be an understudied
mechanism of drug resistance [48]. Sim-
ilarly, identifying high-risk subclonal driv-
ers that might contribute to metastatic
progression and be suitable for therapeutic
intervention is also an area of unmet need.
Through the deep-sequencing of paired
primary and relapsed-disease samples,
TRACERx will distinguish clonal from
subclonal drivers and will relate the clonal
dominance of targetable events to pro-
gression-free survival (PFS) intervals for
targeted therapies in the advanced disease
setting within the DARWIN (Deciphering
Anti-tumour Response With INtratumour
Heterogeneity) Clinical Trial Programme
that is currently in development. The
consortium will attempt to define a new
process for drug development, stratifying
PFS outcomes based on clonal dominance
of the targetable event, and map the
tumour’s subclonal dynamics during the
acquisition of drug resistance.
Metastatic Disease and Defining
the Origins of the Lethal
Subclone
Clonal diversity between primary and
metastatic tumours in the same patient has
been demonstrated in different tumour
types, including but not limited to, breast
[49], pancreatic [6,46], prostate [9], and
medulloblastoma [47]. Longitudinal sam-
ple collection and genomic analysis from
the primary tumour through disease
progression and at the time of death has
the potential to identify the molecular
features and subclonal origin of the
metastatic process. In an interesting case
of prostate cancer, Haffner and colleagues
correlated whole-genome sequencing da-
ta from a primary tumour with three sites
of metastases collected at autopsy 17
years after presentation [9]. Despite
genetic heterogeneity among metastases,
there were many shared events suggest-
ing a monoclonal origin. Through histo-
logical assessment, alongside sequencing,
they identified the lethal metastatic clone
originating from the primary tumour.
Patients who develop terminal metastatic
NSCLC in TRACERx will be asked to
consider enrolling in an autopsy programme
that will be open nationally. For each patient,
TRACERx will have accumulated an un-
precedented amount of genetic data, and
accessing tissue from multiple sites of disease
after death would give some insight into the
evolving constellation of genetic aberrations
and a potential model for the metastatic
process. Circulating biomarkers collected at
this point may add to this model, although as
previously mentioned, the extent to which
these biomarkers reflect tumour genomics in
NSCLC is yet to be fully determined.
Conclusions
The importance of intratumour hetero-
geneity is increasingly recognised as a
driver of tumour progression, drug resis-
tance and treatment failure in solid
tumours [5,6,27,44,47,50–52]. The pres-
ence of subclonal driver events may prove
a significant challenge to biomarker devel-
opment and drug target discovery efforts,
and contribute to drug resistance and poor
survival outcome [10,44,53,54]. Despite
the impressive developments of interna-
tional large-scale sequencing consortia, the
spatial separation of tumour subclones, the
changing nature of the disease over time,
and the impact of such diversity upon
outcome are yet to be addressed [3]. Lung
TRACERx is a large-scale study inte-
grating complex genomic data with
phenotypic clinical annotation and out-
come in order to decipher the hetero-
geneity of the cancer genome and
mutational pathways involved in
NSCLC pathogenesis. It aims to devel-
op clinically meaningful measures of
intratumour heterogeneity to guide pa-
tient management and treatment strat-
ification [55] and to prospectively define
thresholds of tumour heterogeneity for
clinical risk stratification. With increas-
ing awareness of the need to obtain
tissue and genetically profile cancers in
order to stratify treatment, the concept
of longitudinal tissue collection and
analysis has become more acceptable
in oncological practice. In following can-
cers from diagnosis to relapse, tracking the
evolutionary trajectories of tumours in
relation to therapeutic interventions, and
determining the impact of clonal heteroge-
neity on clinical outcomes, TRACERx may
also serve as a model applicable to other
cancer types.
TRACERx is not without its limita-
tions. In determining the full extent of
intratumour heterogeneity, we are reliant
on tissue collected surplus to diagnostic
requirements, and therefore entire tu-
mours are not sequenced. However, with
deep sequencing and multiregion sam-
pling, together with retrospective geno-
mics analysis of residual surplus tumour
tissue guided by the metastatic sample
datasets, we hope to achieve significant
coverage of the relevant tumour genomic
landscape within each patient. Analysing
circulating biomarkers, such as cfDNA
and CTCs, may further complement the
tumour sequencing data and identify
additional genetic aberrations not detected
by primary or metastatic tumour sequenc-
ing. We anticipate that a biopsy of a
metastatic site may not be appropriate in
all patients, but having taken into account
expected rates of attrition, we will have a
sufficient number of cases to meet the
study outcome objectives. Finally, our
ability to detect subclonal somatic events
occurring at low variant allele frequencies
is limited by the power of our existing
methods, but as sequencing and bioinfor-
matics methods advance, TRACERx will
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adapt to incorporate such improvements
in technologies, including the use of deep
whole-genome sequencing datasets in
some cases with no clear genetic driver
events. Overall, TRACERx aims to de-
velop an understanding of the genomic
landscape of NSCLC through the
disease course and the biological role of
underlying genetic events that might
contribute to disease progression.
Optimising understanding of NSCLC
evolutionary processes may help to iden-
tify novel therapeutic targets to improve
clinical outcomes. As the cost of sequenc-
ing decreases and informatics techniques
advance, such large-scale longitudinal
genomic studies may become a central
component to the delivery of precision
cancer medicine.
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